IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
about
Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New TricksIntranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice.Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model.Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease.Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models.Interleukin-33 in health and disease.Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease.Alarmins: Feel the Stress.The IL-1β phenomena in neuroinflammatory diseases.Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye.Interleukin33 deficiency causes tau abnormality and neurodegeneration with Alzheimer-like symptoms in aged mice.Association of interleukin-33 gene polymorphisms with susceptibility to late onset Alzheimer's disease: a meta-analysisLamotrigine Reduces Inflammatory Response and Ameliorates Executive Function Deterioration in an Alzheimer's-Like Mouse Model.IL-33 Acts to Express Schaffer Collateral/CA1 LTP and Regulate Learning and Memory by Targeting MyD88.1st International Conference on Human &Translational Immunology.IL-33-ST2 Axis in Liver Disease: Progression and Challenge.Practical considerations for choosing a mouse model of Alzheimer's disease.Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis.Immune and Imaging Correlates of Mild Cognitive Impairment Conversion to Alzheimer's Disease.Neurotrophin and FGF Signaling Adapter Proteins, FRS2 and FRS3, Regulate Dentate Granule Cell Maturation and Excitatory Synaptogenesis.Behavioral Changes in Mice Lacking Interleukin-33.Targeting IL-33/ST2 signaling: regulation of immune function and analgesia.Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer's disease mouse model 5xFAD.Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility.The Cyanthin Diterpenoid and Sesterterpene Constituents of Hericium erinaceus Mycelium Ameliorate Alzheimer's Disease-Related Pathologies in APP/PS1 Transgenic Mice.Profile of Nancy Ip.Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development.Altered DNA Methylation Patterns Associated With Clinically Relevant Increases in PTSD Symptoms and PTSD Symptom Profiles in Military Personnel.IL-33/ST2 plays a critical role in endothelial cell activation and microglia-mediated neuroinflammation modulation.Critical Roles of IL-33/ST2 Pathway in Neurological Disorders.IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis.Targeting the IL33-NLRP3 axis improves therapy for experimental cerebral malariaClinical PET Imaging of Microglial Activation: Implications for Microglial Therapeutics in Alzheimer's DiseaseEarly Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic ReviewInflammation: the link between comorbidities, genetics, and Alzheimer's diseaseNeuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet?IL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke
P2860
Q28069996-786A1CF3-D457-443E-8554-6447D3AF6B86Q30362847-D686ED2E-70F8-4723-8C71-F0069E4D57C3Q30846817-14C79E2E-8371-485F-949C-3F0ABB674729Q33745149-A7BDCAD4-A7E8-4DED-874C-DF8C3043F3E3Q37630548-0ABA6B3B-02FF-4D16-BA1C-50566184D278Q37713650-F2492A94-866C-4E17-9C25-75C401D7B758Q38891157-38965DC1-D77E-43B0-BF6F-18F23D4C9039Q38957840-FC0F92C3-8215-4D86-AE41-621CC7DBFDFCQ38962792-86E235FE-6449-4461-B43F-50BE15A5B92EQ39023028-052A8D84-3BFF-4912-870C-7FB7B44EC8DEQ39123275-83E39E4B-CFBE-4CB5-9A12-495698C06044Q39324087-3C578E3D-CFB5-4130-96FB-BAB393C65393Q39324207-C1241A2A-72E0-44ED-9BA4-43417E964300Q41197036-9336BEE3-21FF-4E04-ABA4-4D43BD27A49EQ41634210-DCE4A3A5-8603-4A70-A94A-72E43466D445Q42144867-8C42BC62-5D00-416E-8373-31110CEAB382Q44983410-5B8A5D08-2E11-4015-87B4-40937049D263Q45968395-40BD7EB1-0891-410F-BCE9-6774F65D373AQ47127784-FBE859D3-6D48-4000-95C6-131AF757B633Q47135235-2B0EF4C1-D6E0-458D-AD3D-F2B4C7E06ADAQ47148054-0E759683-65B9-40EC-8B2C-32715AA5C17CQ47160572-5E040F09-1424-41B5-946E-302F794DF49FQ47385345-26B9BEF7-7285-4F45-81D3-95FD3E0C7AD3Q47551953-D4A86AE5-A22E-4C2B-A3C5-903EC696CBF5Q47596055-7BB9CBB8-6164-4D80-957D-7A598B1E9685Q47841107-EFF02C05-75FD-47EC-A2DF-BB1E3F5C6037Q49596719-6F2732C7-D8C3-4718-BE56-82041C515DA4Q49804395-67888A07-AD70-44A8-B080-6453C88947BEQ50063691-14C72CBB-AC24-41A1-995C-EF07994902FBQ50115742-5F3E452B-363F-40AE-94F6-EB4D4AD5E63CQ52668986-86DFC794-79BB-4DD8-927B-4F414D98BC31Q54220826-0DC2B945-309F-4813-8D60-23478F45FC57Q54261778-00AE1195-5E60-4CC1-93DA-ADAEDEC5269BQ55514878-F5AE6344-7A7A-4BB9-85F3-7B43288E83D9Q56363934-1ACA756C-65D9-497E-8664-D1ABB7A3AC7BQ57817388-597307CB-1615-457B-85F9-B813BCDB6CBEQ58549216-8DB50A9A-5E76-406F-AFF9-C35ED0943B3AQ58700943-C2096260-623C-4705-9F14-C49EFBF4834CQ58727052-B27F4BDE-9A4B-42F8-9D48-CE21CEDCD19EQ59125563-FFE2B5E2-6E47-4F77-9B44-9D5A582A0580
P2860
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
@nl
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
@ast
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
@en
type
label
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
@nl
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
@ast
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
@en
prefLabel
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
@nl
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
@ast
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.
@en
P2093
P2860
P356
P1476
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
@en
P2093
Amy K Y Fu
Baorong Zhang
Deejay S Y Mak
Foo Y Liew
Ivy C W Chan
Kwok-Wang Hung
Michael Y F Yuen
Nancy Y Ip
Tom H Cheung
Wing-Yu Fu
P2860
P304
P356
10.1073/PNAS.1604032113
P407
P50
P577
2016-04-18T00:00:00Z